Delcath Systems Publishes Positive CHOPIN Trial Results in The Lancet Oncology, Showing Enhanced Survival and Response Rates

summarizeSummary

Delcath Systems announced the publication of its CHOPIN Phase 2 clinical trial results in The Lancet Oncology, highlighting significantly improved survival and response rates for metastatic uveal melanoma patients treated with its Hepatic Delivery System combined with immunotherapy.

check_boxKey Events

• CHOPIN Trial Results Published

  Full results from the randomized Phase 2 CHOPIN clinical trial for metastatic uveal melanoma were published in The Lancet Oncology.

• Significant Efficacy Demonstrated

  The combination of Delcath's Hepatic Delivery System (HDS) with immunotherapy showed a 1-year progression-free survival rate of 54.7% vs 15.8% for HDS alone, and nearly doubled the 2-year overall survival rate (49.6% vs 22.1%).

• Enhanced Hepatic Control and Response

  The combination therapy achieved an objective response rate of 76.3% compared to 39.5% for HDS alone, with a complete response rate of 13% vs 3%.

• Clinical Validation and Commercial Support

  The publication reinforces the synergistic potential of the combination therapy, providing strong clinical validation for Delcath's HEPZATO KIT and supporting its ongoing commercialization and potential for broader adoption.

auto_awesomeAnalysis

This 8-K announces the publication of the full CHOPIN Phase 2 clinical trial results in the highly respected journal, The Lancet Oncology. The detailed data reinforces the significant efficacy of combining Delcath's Hepatic Delivery System (HDS) with immunotherapy for metastatic uveal melanoma, demonstrating substantial improvements in progression-free survival, overall survival, and objective response rates. This publication provides strong clinical validation for the company's core product, supporting its commercialization efforts and potentially expanding its adoption by physicians and patients. The positive results, following recent strong financial performance, further strengthen the company's position in liver-directed oncology.